| Primary Insomnia
Dayvigo vs Belsomra
Side-by-side clinical, coverage, and cost comparison for primary insomnia.Deep comparison between: Dayvigo vs Belsomra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBelsomra has a higher rate of injection site reactions vs Dayvigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Belsomra but not Dayvigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dayvigo
Belsomra
At A Glance
Oral
Once nightly
Orexin receptor antagonist
Oral
Once nightly
Orexin receptor antagonist
Indications
- Primary Insomnia
- Primary Insomnia
Dosing
Primary Insomnia 5 mg once nightly immediately before going to bed with at least 7 hours remaining before awakening; may increase to maximum 10 mg based on clinical response and tolerability. With weak CYP3A inhibitors, maximum dose is 5 mg. With moderate hepatic impairment, initial and maximum dose is 5 mg; not recommended in severe hepatic impairment.
Primary Insomnia Recommended dose 10 mg once nightly within 30 minutes of going to bed (at least 7 hours before planned awakening); may increase to maximum 20 mg once nightly if 10 mg is well-tolerated but not effective. Reduce to 5 mg once nightly with moderate CYP3A inhibitors (max 10 mg); not recommended with strong CYP3A inhibitors.
Contraindications
- Narcolepsy
- Narcolepsy
Adverse Reactions
Most common (>=2%) Somnolence or fatigue, headache, nightmare or abnormal dreams
Serious CNS depressant effects and daytime impairment, sleep paralysis, hypnagogic/hypnopompic hallucinations, cataplexy-like symptoms, complex sleep behaviors, worsening of depression/suicidal ideation
Most common (>=5%) somnolence, headache
Serious CNS depressant effects and daytime impairment, worsening of depression/suicidal ideation, complex sleep behaviors, sleep paralysis, hypnagogic/hypnopompic hallucinations, cataplexy-like symptoms, respiratory depression in patients with compromised respiratory function
Postmarketing palpitations, tachycardia, nausea, vomiting, psychomotor hyperactivity, anxiety, pruritus
Pharmacology
Orexin receptor antagonist; lemborexant competitively blocks binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R (IC50 6.1 nM and 2.6 nM, respectively), suppressing wake drive to facilitate sleep onset and maintenance.
Orexin receptor antagonist; suvorexant blocks the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R (Ki= 0.55 and 0.35 nM, respectively), suppressing wake drive to facilitate sleep onset and maintenance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dayvigo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (12/12)
Belsomra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (12/12)
UnitedHealthcare
Dayvigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (2/8)
Belsomra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (7/8)
Humana
Dayvigo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Belsomra
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Dayvigo.
No savings programs available for Belsomra.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DayvigoView full Dayvigo profile
BelsomraView full Belsomra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.